P J Hesketh
Overview
Explore the profile of P J Hesketh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1752
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Herrstedt J, Clark-Snow R, Ruhlmann C, Molassiotis A, Olver I, Rapoport B, et al.
ESMO Open
. 2024 Mar;
9(2):102195.
PMID: 38458657
No abstract available.
2.
Herrstedt J, Celio L, Hesketh P, Zhang L, Navari R, Chan A, et al.
Support Care Cancer
. 2023 Dec;
32(1):47.
PMID: 38127246
Purpose: This systematic review updates the MASCC/ESMO recommendations for high-emetic-risk chemotherapy (HEC) published in 2016-2017. HEC still includes cisplatin, carmustine, dacarbazine, mechlorethamine, streptozocin, and cyclophosphamide in doses of > 1500...
3.
Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla R, Bruera E, et al.
Ann Oncol
. 2016 Sep;
27(suppl 5):v119-v133.
PMID: 27664248
No abstract available.
4.
Hesketh P, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, et al.
Ann Oncol
. 2014 Mar;
25(7):1340-1346.
PMID: 24608196
Background: NEPA is a novel oral fixed-dose combination of netupitant (NETU), a new highly selective neurokinin-1 (NK1) receptor antagonist (RA) and palonosetron (PALO), a pharmacologically and clinically distinct 5-hydroxytryptamine type...
5.
Roila F, Herrstedt J, Aapro M, Gralla R, Einhorn L, Ballatori E, et al.
Ann Oncol
. 2010 Jun;
21 Suppl 5:v232-43.
PMID: 20555089
No abstract available.
6.
Hesketh P, Grunberg S, Herrstedt J, de Wit R, Gralla R, Carides A, et al.
Support Care Cancer
. 2006 Feb;
14(4):354-60.
PMID: 16450086
Goals Of Work: Prevention of chemotherapy-induced nausea and vomiting (CINV) with standard antiemetics has been more difficult to achieve in female patients. Data from two phase III trials of the...
7.
Roila F, Hesketh P, Herrstedt J
Ann Oncol
. 2005 Nov;
17(1):20-8.
PMID: 16314401
Background: In the late 1990s, several professional organizations convened antiemetic guideline groups and published the findings of these expert panels. Each of these documents was based on analyses of the...
8.
Hesketh P, Van Belle S, Aapro M, Tattersall F, Naylor R, Hargreaves R, et al.
Eur J Cancer
. 2003 May;
39(8):1074-80.
PMID: 12736106
Advances in antiemetic therapy for chemotherapy-induced emesis have resulted in improved protection against symptoms occurring within 24 h of chemotherapy. However, the vomiting which tends to occur beyond 24 h...
9.
Ballen K, Hesketh A, Heyes C, Becker P, Emmons R, Fogarty K, et al.
Bone Marrow Transplant
. 2002 Jan;
28(11):1061-6.
PMID: 11781617
Considerable progress has been made in improving the control of chemotherapy-induced emesis. The impact of available antiemetic options for patients receiving stem cell transplants is unclear, as few prospective data...
10.
Pak S, Penrose W, Hesketh P
Biosens Bioelectron
. 2001 Oct;
16(6):371-9.
PMID: 11672651
A sensitive conductimetric immunosensor has been demonstrated based on an ultrathin platinum film on an oxidized silicon base. The film is about 25 A thick and is seen to consist...